Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

35.42 -0.39 (-1.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
From Scholar Rock
Via Business Wire
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
From Scholar Rock
Via Business Wire
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
From Scholar Rock
Via Business Wire
Scholar Rock Holding Corp. (NASDAQ: SRRK) Near the Top of Equities by Percentage Gain on 10/25
Via Investor Brand Network
Scholar Rock Holding Corp. (NASDAQ: SRRK) Near the Top of Equities by Percentage Gain on 10/6
Via Investor Brand Network
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Provides Corporate Update and Highlights Priorities for 2024
From Scholar Rock, Inc.
Via Business Wire
Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress
From Scholar Rock, Inc.
Via Business Wire
Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
From Scholar Rock
Via Business Wire
Scholar Rock to Participate in Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting
From Scholar Rock
Via Business Wire
Scholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
From Scholar Rock Holding Corporation
Via Business Wire
Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock
From Scholar Rock Holding Corporation
Via Business Wire
Scholar Rock Announces Proposed Public Offering of Common Stock
From Scholar Rock Holding Corporation
Via Business Wire
Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders
From Scholar Rock
Via Business Wire
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy
From Scholar Rock, Inc.
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock to Present at the Jefferies Healthcare Conference
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress
From Scholar Rock, Inc.
Via Business Wire
Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference
From Scholar Rock
Via Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.